The hypolipidemic and liver protective effect of (Z)-N-(2-hydroxyethyl) docos-13-enamide on hyperlipidemic golden hamsters.
- Author:
Yan-Hui SHEN
1
;
Xin JIN
;
Yun ZHAO
;
Gulmira ALTUNBAK
;
Li-Min LIN
;
Ping SHU
;
Xiao WEI
Author Information
1. College of Medicine, Xiamen University, Xiamen 361005, China.
- Publication Type:Journal Article
- MeSH:
Alanine Transaminase;
blood;
Animals;
Aspartate Aminotransferases;
blood;
Cholesterol;
blood;
metabolism;
Cholesterol, HDL;
blood;
Cholesterol, LDL;
blood;
Cricetinae;
Erucic Acids;
chemistry;
pharmacology;
Fatty Liver;
blood;
metabolism;
pathology;
Hyperlipidemias;
blood;
metabolism;
pathology;
Hypolipidemic Agents;
chemistry;
pharmacology;
Liver;
metabolism;
pathology;
Male;
Malondialdehyde;
metabolism;
Mesocricetus;
Random Allocation;
Superoxide Dismutase;
metabolism;
Triglycerides;
blood;
metabolism
- From:
Acta Pharmaceutica Sinica
2012;47(9):1252-1256
- CountryChina
- Language:Chinese
-
Abstract:
This study is to observe preventive effect of (Z)-N-(2-hydroxyethyl) docos-13-enamide on hyperlipidemia and fatty liver of golden hamsters. Hyperlipidemic golden hamsters fed with high-fat diet was administered orally with (Z)-N-(2-hydroxyethyl) docos-13-enamide (10, 20 and 40 mg x kg(-1)) for 5 weeks. Levels of serum and hepatic lipid content, liver histology, hepatic MDA and SOD levels, serum ALT and AST levels were evaluated in golden hamsters. (Z)-N-(2-Hydroxyethyl) docos-13-enamide has a hypolipidemic effect, and could reduce hepatic lipid content, serum ALT and AST levels, hepatic MDA level, increase hepatic SOD activity. (Z)-N-(2-Hydroxyethyl) docos-13-enamide plays an important role in reducing serum lipid, restraining hepatic fatty deposition and protecting liver to get rid of peroxidation injury of hyperlipidemic golden hamsters. The exact lipid-lowering mechanism of (Z)-N-(2-hydroxyethyl) docos-13-enamide needs further investigation.
